Viridian Therapeutics, Inc./DE Restructuring and Related Cost, Cost Incurred to Date
Viridian Therapeutics, Inc./DE (VRDN) had Restructuring and Related Cost, Cost Incurred to Date of $2.40 million as of 2020-12-31, per its 10-K filed 2021-03-26.
Discontinued › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2021-03-26
- 2020-12-31: Restructuring and Related Cost, Cost Incurred to Date $2.40M.
- 2020-09-30: Restructuring and Related Cost, Cost Incurred to Date $2.40M.
- 2020-06-30: Restructuring and Related Cost, Cost Incurred to Date $2.30M.
- 2020-03-31: Restructuring and Related Cost, Cost Incurred to Date $2.20M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2020-12-31 | $2.40M 10-K · filed 2021-03-26 |
| 2020-09-30 | $2.40M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $2.30M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $2.20M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |